Flu is a major cause of morbidity and mortality, and one of the cornerstones of its control is annual vaccination. This Cochrane Review looks at the prevention of seasonal fl u in people aged over 65 years. Despite fi nding a large number of studies, the authors were unable to come to a conclusion about the effect of vaccination in this group, in part because of the low methodological quality of the studies reviewed.
Vaccines for preventing flu in older people
Flu is a major cause of morbidity and mortality, and one of the cornerstones of its control is annual vaccination. This Cochrane Review looks at the prevention of seasonal fl u in people aged over 65 years. Despite fi nding a large number of studies, the authors were unable to come to a conclusion about the effect of vaccination in this group, in part because of the low methodological quality of the studies reviewed.
Vaccine research is complex, and the complexities are multiplied when disparate studies are combined, which also probably accounts for some of the lack of effect seen. First are the general research issues of defi ning variables, in particular which outcomes should be measured. The primary outcomes were those related to the number of cases of fl u or fl u-like illness and fl u-related complications. As the authors note, there are a variety of case defi nitions of fl u, making direct comparison extremely diffi cult and potentially misleading. 1 In addition, a variety of designs can be used, including randomised controlled trials, cohort studies and case-control studies, each of which has a valid, but different, place in vaccine research.
The purposes of vaccination also need to be considered. All vaccines aim to prevent or reduce disease severity in the recipient, but sometimes the additional effect of herd immunity is required. Flu is not particularly infectious in comparison with many other viruses, 2 so herd immunity should be relatively easy to achieve. However, this is clearly not possible if vaccination is restricted to particular groups, unless the infection is found only in those groups, which is not the case in the studies reviewed here.
An adverse event is not necessarily a side-effect
The secondary outcome of the review concerned adverse events. It is good to note that the term 'side-effects' was not used, as many apparently adverse events, including local tenderness and fever, may be the result of stimulating the immune system and are therefore a good if unpleasant outcome. Although it is important to be vigilant, miscategorisation of a normal response or chance happening as an adverse effect may have a damaging infl uence on vaccine uptake. 
Immunity to flu
One key issue specifi c to fl u vaccination is variation in the circulating viruses. Flu changes in two ways -antigenic drift and antigenic shift -and it is the latter that leads to epidemic and pandemic strains. 4 Because vaccines have to be produced and distributed before they can be administered, a judgement has to be made about the composition of the vaccine some months before the fl u season. 5 The accuracy of the forecast about which strains are likely to circulate is therefore crucial to the effectiveness of fl u vaccines.
In the review, the authors variously refer to 'effi cacy' and 'effectiveness' . It is important to differentiate these two terms: effi cacy refers to the effect that the intervention has in the study, and effectiveness refers to its effect in the clinical situation. 6 An added complexity is that there then has to be a decision about effi ciency: is the vaccine worth giving, and is it affordable? This is a value judgement based on a number of considerations, only one of which is effect, and this often accounts for the differences in vaccination schedules.
